ALERT:

Clinical Trial

Clear Cell Renal Cell Carcinoma (ccRCC) Clinical Trial 20203183

[LCID Study Number: 20203183]

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in patients with advanced clear cell renal cell carcinoma (ccRCC).

Disease/Condition: Clear Cell Renal Cell Carcinoma (ccRCC)

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: cancerclinicaltrials@lahey.org

Primary Contact Phone: 781-744-3421

Clinical Trial Details

View NCT ID 04736706 on ClinicalTrials.gov

Protocol #: 20203183

Principal Investigator(s): Brendan J. Connell

Study Coordinator(s): Thea Miller

Trial Phase: Sponsor Initiated Study Phase 3